CD274 and hepatocellular carcinoma: Notably, in trials like KEYNOTE-224 and CheckMate 459, the treatment with nivolumab and pembrolizumab demonstrated better outcomes in patients with PD-L1-positive tumors as compared to those with PD-L1-negative tumors in HCC.